CD8A and plasma cell myeloma: Moreover, CXCL10 suppresses myeloma by recruiting effector CD8+ T, CD4+ T, and NK cells to the tumor site, and combining CXCL10 with radiotherapy enhances its therapeutic efficacy in cervical cancer [81].